MedDataX Logo

Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars

NCT ID: NCT03050723

Last Updated: 2024-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-20

Study Completion Date

2018-01-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, eligible patients with the medical indications (facial lipoatrophy, morphological asymmetry of the face, or debilitating scars) will be treated with Princess® FILLER, and then will return for follow-up assessments 2, 4 and 24 weeks after the treatment. A touch-up treatment may be done 2 weeks after the treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Facial Lipoatrophy Morphological Asymmetry of the Face Debilitating Scars

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Princess® FILLER
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Princess® FILLER

Group Type OTHER

Princess® FILLER

Intervention Type DEVICE

Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Princess® FILLER

Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female 18 years of age or older.
* Presence of a defect, which in the opinion of the Investigator can be corrected by a dermal filler, and is caused by: ° Facial lipoatrophy of moderate severity, or

* Morphological asymmetry of the face, or
* One or more debilitating scars on the face.
* Willingness to abstain from any cosmetic or surgical procedures in the treatment area for the duration of the clinical investigation.
* Willingness to take part in the clinical investigation as evidenced by a personally signed informed consent.

Exclusion Criteria

* Pregnancy, breastfeeding, or unwillingness to use contraception throughout the clinical investigation (for women of child-bearing potential only).
* History of allergic reaction or hypersensitivity to hyaluronic acid.
* History or presence of any autoimmune or connective tissue disease, or current treatment with immune therapy.
* Presence of silicone implant or other non-absorbable tissue filler in the area targeted for intervention, or pre-treatment with any hyaluronic acid filler within the last 6 months.
* Presence of infectious, inflammatory, or proliferative lesions in the area targeted for intervention.
* Treatment with anticoagulant or antiplatelet drugs
* Any disease or condition which, in the Investigator's opinion, represents a safety risk for participation in the study
* Current participation in another clinical trial, or previous treatment with any investigational drug/device within 30 days prior to enrolment
* Institutionalized persons with legally limited civil rights
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Croma-Pharma GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daisy Kopera, Prof.

Role: PRINCIPAL_INVESTIGATOR

Medical University Graz, Austria

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University Graz

Graz, , Austria

Site Status

MÄZ WIEN (Medizinisch Ästhetisches Zentrum Wien)

Vienna, , Austria

Site Status

Ordination Dr. Benjamin Gehl

Vienna, , Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CPH-401-201259

Identifier Type: -

Identifier Source: org_study_id